Govt Acknowledges Chemo Drug Crisis, Allows Price Rise

The central government has officially recognized a critical shortage of Cisplatin and Carboplatin, essential chemotherapy drugs. In response, pharmaceutical companies have been granted permission to increase prices, a decision that signals an official acknowledgment of the ongoing crisis. This development is particularly concerning for cancer patients in India, where a large proportion depend on government healthcare facilities.

While fair pricing is seen as necessary for improved drug quality and production, the government is urged to protect patients. An increase in chemotherapy drug costs could place an unbearable financial strain on families already struggling with medical expenses. There are strong appeals for measures such as highly subsidized rates for government hospitals and a special scheme to provide these life-saving medicines free of cost to poor patients.

Further recommendations include ensuring full coverage of these medications under public healthcare insurance schemes like Ayushman Bharat. The National Pharmaceutical Pricing Authority is expected to strengthen its monitoring of prices and distribution to prevent patient exploitation. The ultimate goal is to guarantee the uninterrupted availability of these crucial drugs across all cancer treatment centers, down to the district government hospital level.